organic compounds\(\def\hfill{\hskip 5em}\def\hfil{\hskip 3em}\def\eqno#1{\hfil {#1}}\)

Journal logoIUCrDATA
ISSN: 2414-3146

N-(4-Meth­­oxy-3-nitro­phen­yl)acetamide

crossmark logo

aDepartment of Environmental Toxicology, Southern University and A&M College, Baton Rouge, LA 70813, USA, and bDepartment of Chemistry, Louisiana State University, Baton Rouge, LA 70803, USA
*Correspondence e-mail: rao_uppu@subr.edu

Edited by W. T. A. Harrison, University of Aberdeen, United Kingdom (Received 29 March 2023; accepted 30 March 2023; online 4 April 2023)

The title compound, C9H10N2O4, crystallizes with a disordered nitro group in twinned crystals. Both the meth­oxy group and the acetamide groups are nearly coplanar with the phenyl ring, and the C—N—C—O torsion angle [0.2 (4)°] is also insignificantly different from zero. Overall, the 12-atom meth­oxy­phenyl­acetamide group is nearly planar, with an r.m.s. deviation of 0.042 Å. The nitro group is twisted out of this plane by about 30°, disordered into two orientations with opposite senses of twist. In the crystal, the N—H group donates a hydrogen bond to a nitro oxygen atom, generating chains propagating in the [101] direction. The amide carbonyl oxygen atom is not involved in the hydrogen bonding.

3D view (loading...)
[Scheme 3D1]
Chemical scheme
[Scheme 1]

Structure description

Belonging to the class of 4-alk­oxy­acetanilides (4-AAs), phenacetin [N-(4-eth­oxy­phen­yl)acetamide] was the first synthetic fever reducer and non-opioid analgesic to go on the market worldwide as early as the 1890s. It is generally believed that the analgesic effects of 4-AAs are due to their actions on the sensory tracts of the spinal cord, while the anti­pyretic actions arise from their actions on the brain where the temperature set point is lowered (Dalmann et al., 2015[Dalmann, R., Daulhac, L., Antri, M., Eschalier, A. & Mallet, C. (2015). Neuropharamacology 91, 63-70.]; Flower & Vane, 1972[Flower, R. J. & Vane, J. R. (1972). Nature, 240, 410-411.]). In vivo, 4-AAs mostly undergo oxidative O-de­alkyl­ation to give N-(4-hydroxphen­yl)acetamide (Brodie & Axelrod, 1948[Brodie, B. & Axelrod, J. (1948). J. Pharmacol. Exp. Ther. 94, 29-38.]; Kapetanović & Mieyal, 1979[Kapetanović, I. M. & Mieyal, J. J. (1979). J. Pharmacol. Exp. Ther. 209, 25-30.]), the clinically relevant analgesic, while small portions may undergo de­acyl­ation, producing carcinogenic, kidney-damaging 4-alk­oxy­anilines and/or their N-oxidation products, namely, N-(4-alk­oxy­phen­yl)hydroxyl­amine and 1-alk­oxy-4-nitroso­benzene (Prescott, 1980[Prescott, L. P. (1980). Br. J. Clin. Pharmacol. 10, 291S-298S.]).

There has been extensive information on phase I and phase II biotransformation of 4-AAs (Estus & Mieyal, 1983[Estus, G. S. & Mieyal, J. J. (1983). Drug Metab. Dispos. 11, 471-476.]; Hinson, 1983[Hinson, J. A. (1983). Environ. Health Perspect. 49, 71-79.]; Kapetanović & Mieyal, 1979[Kapetanović, I. M. & Mieyal, J. J. (1979). J. Pharmacol. Exp. Ther. 209, 25-30.]; Taxak et al., 2013[Taxak, N., Chaitanya Prasad, K. & Bharatam, P. V. (2013). Comput. Theor. Chem. 1007, 48-56.]), but little is known about their biotransformation by non-enzymatic mechanisms, including those mediated by nitric oxide-derived free radical and non-free radical oxidants (viz., nitro­gen dioxide, carbonate radical, and per­oxy­nitrous acid). Studies from our laboratory have shown, for instance, that N-(4-hy­droxy­phen­yl)acetamide forms nitrated products along with varying amounts of dimers when reacted with the said nitric oxide-derived oxidants under physiologically relevant conditions (Deere et al., 2023[Deere, C. J., Agu, O. A., Hines, J. E. III & Uppu, R. M. (2023). Unpublished observations.]; Uppu & Martin, 2004[Uppu, R. M. & Martin, R. J. (2004). The Toxicologist (supplement to Toxicol. Sci.) 84, 319-319]). We reason that similar products (or their positional isomers) may be formed in the reactions of 4-AAs with nitric oxide-derived oxidants or other cellular oxidants like the hypochlorite/hypo­chlorous acid conjugate acid/base system (pH ≃ 7.53).

Towards better understanding of these possibilities and to shed light on mol­ecular targets, we have synthesized the title compound, C9H10N2O4 [N-(4-meth­oxy-3-nitro­phen­yl)acetamide]: crystals grown in water were analyzed by X-ray diffraction. Combined with the recent revelations of mechanisms of action of N-(4-hy­droxy­phen­yl)acetamide through indirect activation of CB1 receptors by 4-amino­phenol [hydrolysis product of N-(4-hy­droxy­phen­yl)acetamide] and endocannabinoid reuptake inhibitor AM404 (Bertolini et al., 2006[Bertolini, A., Ferrari, A., Ottani, A., Guerzoni, S., Tacchi, R. & Leone, S. (2006). CNS Drug Rev. 12, 250-275.]; Zygmunt et al., 2000[Zygmunt, P. M., Chuang, H., Movahed, P., Julius, D. & Högestätt, E. D. (2000). Eur. J. Pharmacol. 396, 39-42.]), the information presented here may provide useful insights into mol­ecular targets for 4-AAs and their nitrated metabolites.

The title compound, shown in Fig. 1[link], crystallizes with a disordered nitro group in twinned crystals. Both the meth­oxy group and the acetamide groups are nearly coplanar with the phenyl ring, with respective torsion angles 0.0 (4)° for C9—O2—C4—C5 and 4.9 (4)° for C7—N1—C1—C2. The C1—N1—C7—O1 torsion angle is also insignificantly different from zero, 0.2 (4)°. Overall, the atoms of the 12-atom meth­oxy­phenyl­acetamide group are almost coplanar with an r.m.s. deviation of 0.042 Å. The nitro group is twisted out of this plane by 23.5 (2) and 35.6 (2)°, disordered into two orientations with opposite senses of twist. The dihedral angle between the two disordered C—NO2 planes is 59.2 (2)°. The N—H group donates inter­molecular hydrogen bonds to the nitro oxygen atom at x − [{1\over 2}], [{1\over 2}] − y, z − [{1\over 2}], with an N1⋯O3A distance of 3.122 (4) Å (Table 1[link]), thereby forming chains propagating in the [101] direction, as shown in Fig. 2[link]. The unit cell is shown in Fig. 3[link]. Inter­estingly, the amide carbonyl oxygen atom is not involved in the hydrogen bonding.

Table 1
Hydrogen-bond geometry (Å, °)

D—H⋯A D—H H⋯A DA D—H⋯A
N1—H1N⋯O3i 0.87 (3) 2.59 (3) 3.410 (5) 157 (2)
N1—H1N⋯O3Ai 0.87 (3) 2.37 (3) 3.122 (4) 145 (3)
Symmetry code: (i) [x-{\script{1\over 2}}, -y+{\script{1\over 2}}, z-{\script{1\over 2}}].
[Figure 1]
Figure 1
The title mol­ecule with displacement ellipsoids drawn at the 50% probability level.
[Figure 2]
Figure 2
The hydrogen-bonding scheme. Only one orientation of the disordered NO2 group is shown.
[Figure 3]
Figure 3
The unit-cell packing. Only one orientation of the disordered NO2 group is shown.

Synthesis and crystallization

N-(4-Meth­oxy-3-nitro­phen­yl)acetamide was synthesized by the acetyl­ation of 4-meth­oxy-3-nitro­aniline using acetic anhydride. Typically, 20 mmol (3.36 g) of 4-meth­oxy-3-nitro­aniline in 30 ml of glacial acetic acid was refluxed for 2 h with 20% molar excess (24 mmol; 2.46 g) of acetic anhydride. The reaction mixture was stirred continuously during the reaction. In the end, the mixture was dried under vacuum, and the residue was purified by recrystallization twice from deionized water. Single crystals of the title compound were grown from an aqueous solution by slow cooling of a hot and nearly saturated solution.

Refinement

Crystal data, data collection and structure refinement details are summarized in Table 2[link]. The crystal chosen for data collection was found to be a three-component nonmerohedral twin with approximate fractions of 0.962: 0.024: 0.014. Refinement was against a twin4.hkl file prepared by TWINABS and the twin fractions were not refined.

Table 2
Experimental details

Crystal data
Chemical formula C9H10N2O4
Mr 210.19
Crystal system, space group Monoclinic, P21/n
Temperature (K) 90
a, b, c (Å) 10.8740 (8), 7.0136 (6), 12.2891 (12)
β (°) 92.313 (5)
V3) 936.48 (14)
Z 4
Radiation type Cu Kα
μ (mm−1) 1.02
Crystal size (mm) 0.32 × 0.09 × 0.04
 
Data collection
Diffractometer Bruker Kappa APEXII DUO CCD
Absorption correction Multi-scan (TWINABS; Bruker, 2016[Bruker (2016). APEX2, SAINT and TWINABS. Bruker AXS Inc., Madison, Wisconsin, USA.])
Tmin, Tmax 0.742, 0.961
No. of measured, independent and observed [I > 2σ(I)] reflections 2937, 1675, 1360
Rint 0.047
(sin θ/λ)max−1) 0.607
 
Refinement
R[F2 > 2σ(F2)], wR(F2), S 0.059, 0.176, 1.08
No. of reflections 1675
No. of parameters 160
H-atom treatment H atoms treated by a mixture of independent and constrained refinement
Δρmax, Δρmin (e Å−3) 0.28, −0.35
Computer programs: APEX2 and SAINT (Bruker, 2016[Bruker (2016). APEX2, SAINT and TWINABS. Bruker AXS Inc., Madison, Wisconsin, USA.]), SHELXT2014/5 (Sheldrick, 2008[Sheldrick, G. M. (2008). Acta Cryst. A64, 112-122.]), SHELXL2017/1 (Sheldrick, 2015[Sheldrick, G. M. (2015). Acta Cryst. C71, 3-8.]), Mercury (Macrae et al., 2020[Macrae, C. F., Sovago, I., Cottrell, S. J., Galek, P. T. A., McCabe, P., Pidcock, E., Platings, M., Shields, G. P., Stevens, J. S., Towler, M. & Wood, P. A. (2020). J. Appl. Cryst. 53, 226-235.]) and publCIF (Westrip, 2010[Westrip, S. P. (2010). J. Appl. Cryst. 43, 920-925.]).

Structural data


Computing details top

Data collection: APEX2 (Bruker, 2016); cell refinement: SAINT (Bruker, 2016); data reduction: SAINT (Bruker, 2016); program(s) used to solve structure: SHELXT2014/5 (Sheldrick, 2008); program(s) used to refine structure: SHELXL2017/1 (Sheldrick, 2015); molecular graphics: Mercury (Macrae et al., 2020); software used to prepare material for publication: publCIF (Westrip, 2010).

N-(4-Methoxy-3-nitrophenyl)acetamide top
Crystal data top
C9H10N2O4F(000) = 440
Mr = 210.19Dx = 1.491 Mg m3
Monoclinic, P21/nCu Kα radiation, λ = 1.54184 Å
a = 10.8740 (8) ÅCell parameters from 3893 reflections
b = 7.0136 (6) Åθ = 5.3–69.2°
c = 12.2891 (12) ŵ = 1.02 mm1
β = 92.313 (5)°T = 90 K
V = 936.48 (14) Å3Needle, yellow
Z = 40.32 × 0.09 × 0.04 mm
Data collection top
Bruker Kappa APEXII DUO CCD
diffractometer
1675 independent reflections
Radiation source: IµS microfocus1360 reflections with I > 2σ(I)
QUAZAR multilayer optics monochromatorRint = 0.047
φ and ω scansθmax = 69.4°, θmin = 5.3°
Absorption correction: multi-scan
(TWINABS; Bruker, 2016)
h = 1313
Tmin = 0.742, Tmax = 0.961k = 88
2937 measured reflectionsl = 1414
Refinement top
Refinement on F20 restraints
Least-squares matrix: fullHydrogen site location: mixed
R[F2 > 2σ(F2)] = 0.059H atoms treated by a mixture of independent and constrained refinement
wR(F2) = 0.176 w = 1/[σ2(Fo2) + (0.0926P)2 + 0.7816P]
where P = (Fo2 + 2Fc2)/3
S = 1.08(Δ/σ)max < 0.001
1675 reflectionsΔρmax = 0.28 e Å3
160 parametersΔρmin = 0.35 e Å3
Special details top

Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; correlations between esds in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell esds is used for estimating esds involving l.s. planes.

Refinement. Twinned crystal. Refinement was vs. an HKLF4 file prepared by TWINABS. All H atoms were located in difference maps and those on C were thereafter treated as riding in geometrically idealized positions with C—H distances of 0.95 Å for phenyl and 0.98 Å for methyl. The coordinates of the amide H atom were refined. Uiso(H) values were constrained to be 1.2Ueq for the attached atom (1.5 for methyl).

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2) top
xyzUiso*/UeqOcc. (<1)
O10.29551 (15)0.2148 (3)0.64386 (16)0.0309 (5)
O20.84160 (14)0.4030 (3)0.47776 (15)0.0291 (5)
O30.6667 (4)0.4337 (10)0.7443 (4)0.0382 (13)0.500 (6)
O40.8325 (3)0.3096 (8)0.6813 (4)0.0450 (16)0.500 (6)
O3A0.6722 (4)0.3056 (10)0.7606 (3)0.0377 (13)0.500 (6)
O4A0.8073 (3)0.4813 (6)0.6859 (3)0.0366 (13)0.500 (6)
N10.34765 (17)0.1800 (3)0.46794 (18)0.0246 (5)
H1N0.323 (3)0.145 (4)0.403 (3)0.030*
N20.72034 (18)0.3692 (3)0.67532 (19)0.0314 (6)
C10.4726 (2)0.2346 (3)0.4747 (2)0.0248 (6)
C20.5355 (2)0.2771 (3)0.5717 (2)0.0248 (6)
H20.4951950.2698730.6387380.030*
C30.6593 (2)0.3309 (4)0.5696 (2)0.0249 (6)
C40.7224 (2)0.3447 (3)0.4729 (2)0.0252 (6)
C50.6570 (2)0.2991 (4)0.3768 (2)0.0278 (6)
H50.6967890.3057180.3094880.033*
C60.5349 (2)0.2441 (3)0.3779 (2)0.0255 (6)
H60.4925900.2120810.3112630.031*
C70.2676 (2)0.1729 (3)0.5507 (2)0.0260 (6)
C80.1392 (2)0.1083 (4)0.5162 (2)0.0316 (6)
H8A0.1028110.0392860.5763480.047*
H8B0.1432200.0240680.4528650.047*
H8C0.0884320.2197500.4971650.047*
C90.9015 (2)0.4168 (4)0.3751 (2)0.0308 (6)
H9A0.9065090.2899130.3422080.046*
H9B0.9846990.4682910.3876080.046*
H9C0.8540220.5016140.3259490.046*
Atomic displacement parameters (Å2) top
U11U22U33U12U13U23
O10.0196 (9)0.0424 (11)0.0312 (12)0.0022 (7)0.0055 (7)0.0013 (8)
O20.0149 (8)0.0369 (11)0.0359 (11)0.0033 (6)0.0060 (7)0.0021 (8)
O30.036 (2)0.052 (4)0.027 (2)0.003 (2)0.0027 (17)0.009 (2)
O40.0188 (19)0.078 (4)0.037 (3)0.0051 (18)0.0031 (15)0.010 (2)
O3A0.033 (2)0.052 (4)0.027 (2)0.0082 (19)0.0026 (16)0.002 (2)
O4A0.0236 (19)0.048 (3)0.039 (2)0.0111 (16)0.0014 (15)0.0081 (18)
N10.0163 (10)0.0324 (12)0.0251 (12)0.0046 (7)0.0012 (8)0.0011 (9)
N20.0188 (10)0.0402 (13)0.0349 (14)0.0045 (9)0.0023 (9)0.0080 (11)
C10.0164 (11)0.0231 (12)0.0348 (15)0.0006 (8)0.0023 (9)0.0026 (10)
C20.0172 (11)0.0254 (13)0.0320 (15)0.0010 (8)0.0048 (9)0.0030 (10)
C30.0196 (12)0.0275 (13)0.0276 (14)0.0002 (9)0.0015 (9)0.0024 (10)
C40.0156 (11)0.0237 (12)0.0368 (16)0.0005 (8)0.0061 (9)0.0038 (10)
C50.0229 (12)0.0311 (14)0.0299 (15)0.0003 (9)0.0081 (10)0.0019 (11)
C60.0223 (12)0.0283 (13)0.0261 (14)0.0009 (9)0.0029 (9)0.0028 (10)
C70.0177 (12)0.0259 (13)0.0346 (16)0.0002 (9)0.0019 (10)0.0038 (10)
C80.0177 (12)0.0337 (14)0.0433 (17)0.0034 (9)0.0016 (10)0.0016 (12)
C90.0192 (12)0.0397 (15)0.0343 (15)0.0022 (10)0.0087 (10)0.0011 (11)
Geometric parameters (Å, º) top
O1—C71.209 (3)C2—H20.9500
O2—C41.358 (3)C3—C41.399 (3)
O2—C91.446 (3)C4—C51.391 (4)
O3—N21.142 (5)C5—C61.383 (3)
O4—N21.288 (5)C5—H50.9500
O3A—N21.271 (5)C6—H60.9500
O4A—N21.233 (4)C7—C81.511 (3)
N1—C71.366 (3)C8—H8A0.9800
N1—C11.411 (3)C8—H8B0.9800
N1—H1N0.87 (3)C8—H8C0.9800
N2—C31.459 (3)C9—H9A0.9800
C1—C21.383 (4)C9—H9B0.9800
C1—C61.394 (3)C9—H9C0.9800
C2—C31.400 (3)
C4—O2—C9116.4 (2)C6—C5—C4120.9 (2)
C7—N1—C1127.4 (2)C6—C5—H5119.5
C7—N1—H1N119.2 (19)C4—C5—H5119.5
C1—N1—H1N113.4 (19)C5—C6—C1121.4 (2)
O4A—N2—O3A118.5 (3)C5—C6—H6119.3
O3—N2—O4126.7 (4)C1—C6—H6119.3
O3—N2—C3120.4 (3)O1—C7—N1123.6 (2)
O4A—N2—C3122.0 (3)O1—C7—C8122.2 (2)
O3A—N2—C3118.8 (3)N1—C7—C8114.3 (2)
O4—N2—C3112.7 (3)C7—C8—H8A109.5
C2—C1—C6119.0 (2)C7—C8—H8B109.5
C2—C1—N1123.4 (2)H8A—C8—H8B109.5
C6—C1—N1117.6 (2)C7—C8—H8C109.5
C1—C2—C3119.0 (2)H8A—C8—H8C109.5
C1—C2—H2120.5H8B—C8—H8C109.5
C3—C2—H2120.5O2—C9—H9A109.5
C4—C3—C2122.6 (2)O2—C9—H9B109.5
C4—C3—N2121.5 (2)H9A—C9—H9B109.5
C2—C3—N2115.9 (2)O2—C9—H9C109.5
O2—C4—C5124.1 (2)H9A—C9—H9C109.5
O2—C4—C3118.9 (2)H9B—C9—H9C109.5
C5—C4—C3117.0 (2)
C7—N1—C1—C24.9 (4)C9—O2—C4—C50.0 (4)
C7—N1—C1—C6175.6 (2)C9—O2—C4—C3179.3 (2)
C6—C1—C2—C30.9 (4)C2—C3—C4—O2178.2 (2)
N1—C1—C2—C3179.6 (2)N2—C3—C4—O22.8 (4)
C1—C2—C3—C40.4 (4)C2—C3—C4—C51.1 (4)
C1—C2—C3—N2178.6 (2)N2—C3—C4—C5177.9 (2)
O3—N2—C3—C4147.7 (4)O2—C4—C5—C6178.8 (2)
O4A—N2—C3—C429.0 (4)C3—C4—C5—C60.5 (4)
O3A—N2—C3—C4160.7 (4)C4—C5—C6—C10.8 (4)
O4—N2—C3—C437.3 (4)C2—C1—C6—C51.5 (4)
O3—N2—C3—C233.3 (5)N1—C1—C6—C5179.0 (2)
O4A—N2—C3—C2152.0 (3)C1—N1—C7—O10.2 (4)
O3A—N2—C3—C218.4 (5)C1—N1—C7—C8179.9 (2)
O4—N2—C3—C2141.8 (3)
Hydrogen-bond geometry (Å, º) top
D—H···AD—HH···AD···AD—H···A
N1—H1N···O3i0.87 (3)2.59 (3)3.410 (5)157 (2)
N1—H1N···O3Ai0.87 (3)2.37 (3)3.122 (4)145 (3)
Symmetry code: (i) x1/2, y+1/2, z1/2.
 

Funding information

The authors acknowledge the support from the National Institutes of Health (NIH) through the National Institute of General Medical Science (NIGMS) grant No. 5 P2O GM103424–17 and the US Department of Education (US DoE; Title III, HBGI Part B grant No. P031B040030). Its contents are solely the responsibility of authors and do not represent the official views of NIH, NIGMS, or US DoE. The upgrade of the diffractometer was made possible by grant No. LEQSF(2011–12)-ENH-TR-01, administered by the Louisiana Board of Regents.

References

First citationBertolini, A., Ferrari, A., Ottani, A., Guerzoni, S., Tacchi, R. & Leone, S. (2006). CNS Drug Rev. 12, 250–275.  Web of Science CrossRef PubMed CAS Google Scholar
First citationBrodie, B. & Axelrod, J. (1948). J. Pharmacol. Exp. Ther. 94, 29–38.  PubMed CAS Web of Science Google Scholar
First citationBruker (2016). APEX2, SAINT and TWINABS. Bruker AXS Inc., Madison, Wisconsin, USA.  Google Scholar
First citationDalmann, R., Daulhac, L., Antri, M., Eschalier, A. & Mallet, C. (2015). Neuropharamacology 91, 63–70.  Web of Science CrossRef CAS Google Scholar
First citationDeere, C. J., Agu, O. A., Hines, J. E. III & Uppu, R. M. (2023). Unpublished observations.  Google Scholar
First citationEstus, G. S. & Mieyal, J. J. (1983). Drug Metab. Dispos. 11, 471–476.  CAS PubMed Web of Science Google Scholar
First citationFlower, R. J. & Vane, J. R. (1972). Nature, 240, 410–411.  CrossRef CAS PubMed Web of Science Google Scholar
First citationHinson, J. A. (1983). Environ. Health Perspect. 49, 71–79.  CrossRef CAS PubMed Google Scholar
First citationKapetanović, I. M. & Mieyal, J. J. (1979). J. Pharmacol. Exp. Ther. 209, 25–30.  PubMed Web of Science Google Scholar
First citationMacrae, C. F., Sovago, I., Cottrell, S. J., Galek, P. T. A., McCabe, P., Pidcock, E., Platings, M., Shields, G. P., Stevens, J. S., Towler, M. & Wood, P. A. (2020). J. Appl. Cryst. 53, 226–235.  Web of Science CrossRef CAS IUCr Journals Google Scholar
First citationPrescott, L. P. (1980). Br. J. Clin. Pharmacol. 10, 291S–298S.  CrossRef PubMed Web of Science Google Scholar
First citationSheldrick, G. M. (2008). Acta Cryst. A64, 112–122.  Web of Science CrossRef CAS IUCr Journals Google Scholar
First citationSheldrick, G. M. (2015). Acta Cryst. C71, 3–8.  Web of Science CrossRef IUCr Journals Google Scholar
First citationTaxak, N., Chaitanya Prasad, K. & Bharatam, P. V. (2013). Comput. Theor. Chem. 1007, 48–56.  Web of Science CrossRef CAS Google Scholar
First citationUppu, R. M. & Martin, R. J. (2004). The Toxicologist (supplement to Toxicol. Sci.) 84, 319–319  Google Scholar
First citationWestrip, S. P. (2010). J. Appl. Cryst. 43, 920–925.  Web of Science CrossRef CAS IUCr Journals Google Scholar
First citationZygmunt, P. M., Chuang, H., Movahed, P., Julius, D. & Högestätt, E. D. (2000). Eur. J. Pharmacol. 396, 39–42.  Web of Science CrossRef PubMed CAS Google Scholar

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.

Journal logoIUCrDATA
ISSN: 2414-3146